Annual meeting 2026 to take place on 22 May
Antimicrobial resistance is one of the gravest public health threats of our time – but the tools we need to combat it are not being developed, deployed, or sustained.
The challenge goes far beyond new antibiotics.
Tackling AMR demands a whole-ecosystem response, but every pillar involved suffers from the same underlying problem: a fundamentally broken business model.
Volume-based pricing punishes restraint, discourages prevention, and makes it nearly impossible to sustain a commercial case for products intended for sparing use.
But what can we learn from entirely different industries? Netflix and Spotify replaced an outdated “pay-per-unit” logic with predictable, sustainable revenue streams rewarding the creation of value rather than the volume of consumption.
Now, this same principle may be applied in healthcare. In June 2026, the European Union will take a landmark step: the entry into force of the Transferable Exclusivity Voucher (TEV) for antimicrobials – in essence, a subscription model for antibiotics.
This is a turning point. And it deserves a serious, cross-sector discussion.
Join us on 22 May 2026 in Utrecht as we explore the provocative question: can subscription models do for antimicrobials what Netflix and Spotify did for film and music?
Speakers and organizations scheduled to speak include:
health economist Brooke Nichols,
Remko van Leeuwen (former board member of the BEAM Alliance),
Rob Mayfield (InFECT-TT),
The market failed. The model can fix it. Join the conversation.
Location: De Moestuin, Utrecht
Time: 11:00-16:00, followed by networking